The evidence does not support calling the use of Mounjaro or Ozempic cheating. The charge treats body weight as a test of will, and studies of heritability and appetite contradict that premise.
The "Easy Way Out" Argument
The charge holds that losing weight with a drug is morally inferior to dieting and exercise. In 2026, Standen and colleagues reported two preregistered online experiments with US adults. In Study 1, 607 participants rated a fictional user of a glucagon-like peptide-1 (GLP-1) drug. They judged that person more negatively than a dieter or someone who had not lost weight.
A 2026 experiment by Post and colleagues described a woman who lost 15% of her body weight. Stigma toward her was higher when the loss came from a GLP-1 drug rather than diet and exercise. The effect was explained by the belief that she had taken a shortcut. Both studies used fictional scenarios. The charge rests on the premise that body weight is under voluntary control.
Is Obesity a Willpower Problem?
Obesity is not simply a willpower problem. Body weight is substantially heritable, and appetite rises after weight loss.
In 1990, Stunkard and colleagues studied identical twins who had been raised apart. Their body mass index, a measure of weight relative to height, was closely matched. The correlations were 0.70 in men and 0.66 in women, where 1 is a perfect match. A shared upbringing added little to that similarity. These figures estimate how much of obesity is inherited across a population, not how fixed any one person's weight is.
In 2011, Sumithran and colleagues enrolled 50 adults in Melbourne on a very-low-calorie diet. After a mean loss of 13.5 kilograms, hormones that regulate hunger shifted toward increased appetite. One year later, several had not returned to baseline, and hunger remained higher.
What Doctors Say About Weight Loss Drugs
Major medical bodies treat obesity as a disease and drug treatment as legitimate care. The American Medical Association's Policy H-440.842, adopted in 2013 and reaffirmed in 2023, recognizes obesity as a disease state.
Grunvald and colleagues published a 2022 American Gastroenterological Association guideline. It strongly recommended drug treatment alongside lifestyle intervention for eligible adults who responded inadequately to lifestyle changes. It predated Zepbound's approval.
Rubino and colleagues' 2020 international consensus statement was endorsed by US bodies including the Endocrine Society. It called the assumption that body weight is entirely under voluntary control at odds with biological and clinical evidence.
How Tirzepatide Works
Tirzepatide acts on hormone signals that regulate appetite, but its approval and trials pair it with diet and activity. The Zepbound label describes it as activating the receptors for two hormones involved in regulating food intake, glucose-dependent insulinotropic polypeptide and GLP-1. The label says it decreases calorie intake.
Eli Lilly sells tirzepatide as Mounjaro for type 2 diabetes, and its label does not cover weight management. Zepbound is the tirzepatide brand approved for weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic, according to its label, is Novo Nordisk's semaglutide for type 2 diabetes, and Wegovy is the semaglutide brand for weight management.
Zepbound is approved "in combination with a reduced-calorie diet and increased physical activity." In the 2022 SURMOUNT-1 trial, Jastreboff and colleagues gave every arm lifestyle counseling. Over 72 weeks, adults without diabetes on the 15 mg dose lost a mean 20.9% of body weight, compared with 3.1% on placebo.
In the 2024 SURMOUNT-4 trial, Aronne and colleagues randomly switched some participants to placebo after 36 weeks of tirzepatide. Over the next 52 weeks, that group regained 14.0% of body weight, while those who continued lost a further 5.5%.
Compounded tirzepatide is made by pharmacies rather than Eli Lilly. The US Food and Drug Administration (FDA) does not approve it or review it for safety, effectiveness, or quality. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and compounded copies of the approved drug are now restricted.
Weight Stigma, Drive, and the Cheating Label
The cheating label is a form of weight stigma, and stigma predicts worse outcomes rather than stronger effort. In a 2013 US cohort study by Sutin and Terracciano, people reporting weight discrimination were about 2.5 times as likely to later develop obesity. The study was observational. In a 2011 experiment, Schvey and colleagues showed 73 women a stigmatizing video or a neutral video. Those with overweight ate over three times as many calories after the stigmatizing one.
In men with obesity, weight loss is linked to higher total testosterone, according to a 2013 meta-analysis by Corona and colleagues. The finding concerns weight loss in general, not tirzepatide or motivation. Whether testosterone affects motivation is a separate question.
The cheating charge fails on its own premise. Tirzepatide is better judged as a medical treatment, by its trial results and limits, than as a test of character.
Sources
- Public views of GLP-1 drugs: Standen et al., Int J Obes, 2026; Post et al., Stigma Health, 2026
- Heritability and appetite: Stunkard et al., N Engl J Med, 1990; Sumithran et al., N Engl J Med, 2011
- Medical positions: AMA Policy H-440.842, 2023; Grunvald et al., Gastroenterology (AGA guideline), 2022; Rubino et al., Nat Med, 2020
- Tirzepatide and semaglutide: Zepbound label, 2026; Mounjaro label, 2026; Ozempic label, 2026; Jastreboff et al., N Engl J Med (SURMOUNT-1), 2022; Aronne et al., JAMA (SURMOUNT-4), 2024; FDA Concerns with Unapproved GLP-1 Drugs, 2026; FDA Clarifies Policies for Compounders, 2026
- Weight stigma and drive: Sutin and Terracciano, PLoS One, 2013; Schvey et al., Obesity, 2011; Corona et al., Eur J Endocrinol, 2013